Send us Feedback

MediciNova (MNOV)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Developer of New Treatment for Severe Asthma Episodes Expects Phase 2 Clinical Trial Results Soon
Marketwire  Apr 19  Comment 
LOS ANGELES, CA -- (Marketwire) -- 04/19/12 -- In an exclusive Expert Briefing at BioMedReports, Yuichi Iwaki, M.D., Ph.D., the Founder, President and Chief Executive Officer of MediciNova, Inc. (NASDAQ: MNOV) tells investors about a promising
MediciNova Appoints David O'Toole CPA to its Board of Directors
Globe Newswire  Apr 10  Comment 
SAN DIEGO, April 10, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number:4875), today announced the appointment of
MediciNova Reports Fourth Quarter and Full Year 2011 Results
Globe Newswire  Mar 29  Comment 
SAN DIEGO, March 29, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results
From Earlier: MediciNova Completes Enrollment in Phase 2 MN-221 Trial Treating Patients Suffering from Acute Exacerbations of Asthma
Benzinga  Mar 22  Comment 
MediciNova, Inc. (Nasdaq: MNOV) and the Jasdaq Market of the Osaka Securities Exchange, yesterday announced it has completed enrollment in its Phase 2 clinical trial (MN-221-CL-007) evaluating the safety and efficacy of MN-221 for treatment of...
From Earlier: MediciNova Receives Notice of a Japanese Patent Allowance for a Method of Treating Neuropathic Pain
Benzinga  Mar 14  Comment 
MediciNova, Inc. (Nasdaq: MNOV) and the Jasdaq Market yesterday announced that it has received a Notice of Allowance from the Japanese Patent Office for a pending patent application, which covers the use of ibudilast (MN-166) for the treatment of...
MediciNova (MNOV) Gets Notice of Allowance in Japan for MN-166 Patent Application
StreetInsider.com  Mar 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/MediciNova+%28MNOV%29+Gets+Notice+of+Allowance+in+Japan+for+MN-166+Patent+Application/7266646.html for the full story.
MediciNova Receives a Notice of Patent Allowance for a Method of Treating Progressive Multiple Sclerosis
Globe Newswire  Feb 1  Comment 
SAN DIEGO, Calif., Feb. 1, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), today announced that it has received a
MediciNova (MNOV) Receives Notice of Allowance for MS-Treatment Ibudilast Patent
StreetInsider.com  Feb 1  Comment 
MediciNova and University of Colorado Boulder Collaborate on Potential Novel Therapy for Traumatic Brain Injury
Globe Newswire  Jan 16  Comment 
SAN DIEGO, Jan. 16, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), and the University of Colorado
MediciNova, Inc. Appoints Kousuke Nakata to Its Board of Directors
Globe Newswire  Nov 30  Comment 
SAN DIEGO, Calif., Nov. 30, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), today announced the appointment of Mr.




more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 




References

Retrieved from "http://www.wikinvest.com/stock/MediciNova_(MNOV)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki